This study evaluated the pharmacokinetics of topical creams containing 15% paromomycin (“paromomycin alone”) and 15% paromomycin plus 0.5% gentamicin (WR 279,396) in patients with cutaneous leishmaniasis. The investigational creams were applied topically to all lesions once daily for 20 days. Plasma samples were analyzed for simultaneous quantitation of paromomycin and gentamicin isomers and total gentamicin. Pharmacokinetic parameters for gentamicin could not be calculated because detectable levels were rarely evident. After one application, the paromomycin area under the concentration-time curve from 0 to 24 h (AUC0–24) was 2,180 +/- 2,621 ng · h/ml (mean +/- standard deviation [SD]) for the paromomycin-alone group and 975.6 +/- 1,078 ng ...
International audienceBACKGROUND: There is a need for a simple and efficacious treatment for cutaneo...
Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimonia...
Parenteral pentavalent antimonials remain the standard therapy for cutaneous leishmaniasis. More eff...
This study evaluated the pharmacokinetics of topical creams containing 15% paromomycin (“paromomycin...
In this randomized, double-blinded Phase 2 trial, 30 patients with Leishmania panamensis cutaneous l...
BackgroundParomomycin-based topical treatments were shown to be effective in curing cutaneous leishm...
The objective of this work is to study the pharmacokinetics of Paromomycin (PM) in kala-azar patient...
BACKGROUND: High cost, poor compliance, and systemic toxicity have limited the use of pentavalent an...
Abstract. A double-blind, randomized trial was undertaken in Guatemala to determine the therapeutic ...
The nitroimidazole DNDI-0690 is a clinical drug candidate for visceral leishmaniasis (VL) that also ...
High cost, poor compliance, and systemic toxicity have limited the use of pentavalent antimony compo...
This thesis focuses on bioanalytical method development and validation of antileishmanial drugs amph...
Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite Leishmania, affe...
This is an open study to compare the cure rate of cutaneous leishmaniasis caused by L. major and tre...
BACKGROUND: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard...
International audienceBACKGROUND: There is a need for a simple and efficacious treatment for cutaneo...
Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimonia...
Parenteral pentavalent antimonials remain the standard therapy for cutaneous leishmaniasis. More eff...
This study evaluated the pharmacokinetics of topical creams containing 15% paromomycin (“paromomycin...
In this randomized, double-blinded Phase 2 trial, 30 patients with Leishmania panamensis cutaneous l...
BackgroundParomomycin-based topical treatments were shown to be effective in curing cutaneous leishm...
The objective of this work is to study the pharmacokinetics of Paromomycin (PM) in kala-azar patient...
BACKGROUND: High cost, poor compliance, and systemic toxicity have limited the use of pentavalent an...
Abstract. A double-blind, randomized trial was undertaken in Guatemala to determine the therapeutic ...
The nitroimidazole DNDI-0690 is a clinical drug candidate for visceral leishmaniasis (VL) that also ...
High cost, poor compliance, and systemic toxicity have limited the use of pentavalent antimony compo...
This thesis focuses on bioanalytical method development and validation of antileishmanial drugs amph...
Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite Leishmania, affe...
This is an open study to compare the cure rate of cutaneous leishmaniasis caused by L. major and tre...
BACKGROUND: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard...
International audienceBACKGROUND: There is a need for a simple and efficacious treatment for cutaneo...
Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimonia...
Parenteral pentavalent antimonials remain the standard therapy for cutaneous leishmaniasis. More eff...